Mutant Isocitrate Dehydrogenase 1 Expression Enhances Response of Gliomas to the Histone Deacetylase Inhibitor Belinostat
Open Access
- 4 May 2023
- journal article
- research article
- Published by MDPI AG in Tomography
- Vol. 9 (3) , 942-954
Abstract
Histone deacetylase inhibitors (HDACis) are drugs that target the epigenetic state of cells by modifying the compaction of chromatin through effects on histone acetylation. Gliomas often harbor a mutation of isocitrate dehydrogenase (IDH) 1 or 2 that leads to changes in their epigenetic state presenting a hypermethylator phenotype. We postulated that glioma cells with IDH mutation, due to the presence of epigenetic changes, will show increased sensitivity to HDACis. This hypothesis was tested by expressing mutant IDH1 with a point alteration—converting arginine 132 to histidine—within glioma cell lines that contain wild-type IDH1. Glioma cells engineered to express mutant IDH1 produced D-2-hydroxyglutarate as expected. When assessed for response to the pan-HDACi drug belinostat, mutant IDH1-expressing glioma cells were subjected to more potent inhibition of growth than the corresponding control cells. Increased sensitivity to belinostat correlated with the increased induction of apoptosis. Finally, a phase I trial assessing the addition of belinostat to standard-of-care therapy for newly diagnosed glioblastoma patients included one patient with a mutant IDH1 tumor. This mutant IDH1 tumor appeared to display greater sensitivity to the addition of belinostat than the other cases with wild-type IDH tumors based on both standard magnetic resonance imaging (MRI) and advanced spectroscopic MRI criteria. These data together suggest that IDH mutation status within gliomas may serve as a biomarker of response to HDACis.Keywords
Funding Information
- National Cancer Institute (U01 CA172027, U01 CA264039, F31CA247564)
- National Cancer Institute (U01 CA172027, U01 CA264039, F31CA247564)
This publication has 37 references indexed in Scilit:
- IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in gliomaNeuro-Oncology, 2013
- IDH1 mutation is sufficient to establish the glioma hypermethylator phenotypeNature, 2012
- Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolomeProceedings of the National Academy of Sciences, 2011
- DNA Methylation, Isocitrate Dehydrogenase Mutation, and Survival in GliomaJNCI: Journal of the National Cancer Institute, 2011
- Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent DioxygenasesCancer Cell, 2011
- The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-HydroxyglutarateCancer Cell, 2010
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarateNature, 2009
- Histone deacetylase inhibitors: Potential in cancer therapyJournal of Cellular Biochemistry, 2009
- IDH1andIDH2Mutations in GliomasNew England Journal of Medicine, 2009
- An Integrated Genomic Analysis of Human Glioblastoma MultiformeScience, 2008